Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Role of therapeutic drug monitoring for protease inhibitors
Autore:
John, L; Marra, F; Ensom, MHH;
Indirizzi:
Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC V5Z 1M9, Canada Univ British Columbia Vancouver BC Canada V5Z 1M9 ver, BC V5Z 1M9, Canada Vancouver Hosp & Hlth Sci Ctr, Vancouver, BC V5Z 1M9, Canada Vancouver Hosp & Hlth Sci Ctr Vancouver BC Canada V5Z 1M9 V5Z 1M9, Canada Childrens & Womens Hlth Ctr British Columbia, Pharm Dept 0B7, Vancouver, BC V6H 3V4, Canada Childrens & Womens Hlth Ctr British Columbia Vancouver BC Canada V6H 3V4
Titolo Testata:
ANNALS OF PHARMACOTHERAPY
fascicolo: 6, volume: 35, anno: 2001,
pagine: 745 - 754
SICI:
1060-0280(200106)35:6<745:ROTDMF>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
PERFORMANCE LIQUID-CHROMATOGRAPHY; ACTIVE ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-INFECTED PATIENTS; HUMAN PLASMA; INDINAVIR; SAQUINAVIR; RITONAVIR; NELFINAVIR; FAILURE;
Keywords:
pharmacokinetics; protease inhibitors; therapeutic drug monitoring;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
41
Recensione:
Indirizzi per estratti:
Indirizzo: Ensom, MHH Childrens & Womens Hlth Ctr British Columbia, Pharm Dept 0B7, 4480 Oak St,Vancouver, BC V6H 3V4, Canada Childrens & Womens Hlth Ctr British Columbia 4480 Oak St Vancouver BC Canada V6H 3V4
Citazione:
L. John et al., "Role of therapeutic drug monitoring for protease inhibitors", ANN PHARMAC, 35(6), 2001, pp. 745-754

Abstract

OBJECTIVE: To review the role of therapeutic drug monitoring (TDM) for protease inhibitors in the treatment of HIV infection. DATA SOURCES: Primary articles were identified using MEDLINE (1966-October2000), EMBASE (1987-October 2000), AIDSLINE (1980-October 2000), Current Contents, PubMed, and Medscape. Further articles were identified from bibliographic review of primary articles and review papers. Abstracts presented at the World AIDS Conference, Interscience Conference on Antimicrobial Agents and Chemotherapy, and Conference on Retroviruses and Opportunistic Infections were also identified from 1997 to 2000. STUDY SELECTION AND DATA EXTRACTION: All English-language, prospective clinical trials, as well as selected retrospective studies and case series, pertaining to therapeutic drug monitoring of protease inhibitors were included. DATA SYNTHESIS: A number of clinical studies have found a good relationship between concentration and pharmacologic response and/or toxicity as well as wide interpatient variability in the pharmacokinetics of protease inhibitors. There also is some preliminary evidence of the usefulness of plasma drug concentrations to guide dosage adjustments of protease inhibitors in patients with liver dysfunction. Furthermore, there is preliminary evidence of a relationship between drug concentrations and resistance. CONCLUSIONS: A number of clinical studies support the usefulness of TDM ofprotease inhibitors. However, before TDM can be of the most value, furtherevaluation requires simplified and standardized assays to be performed routinely by clinical laboratories; determination of the appropriate target concentration and therapeutic range, as well as the best predictor of pharmacologic response; and refined interpretation of plasma drug concentrations. Randomized, controlled clinical trials of patient outcomes are needed to assess the clinical utility of TDM for protease inhibitors.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/04/20 alle ore 11:41:59